Liu Liang,Li Ting,Wong Kam Wai,Jiang Zhihong,Zhou Hua
申请号：
US201514620141
公开号：
US9955676(B2)
申请日:
2015.02.11
申请国别(地区):
美国
年份:
2018
代理人:
Spruson & Ferguson (Hong Kong) Limited
摘要：
The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.
